Results 241 to 250 of about 175,064 (329)

Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
This national cohort study of patients surgically resected for colon cancer, during 2007–2021, compares survival outcomes of patients with and without inflammatory bowel diseases. The main results were that overall survival, recurrence‐free survival and cancer‐specific survival were lower in patients with IBD.
Erik Lundqvist, Karin Westberg, Sol Erika Boman, Ida H. Myrberg, Åsa H. Everhov, Pär Myrelid, Bengt Glimelius, Anna Martling, Caroline Nordenvall   +8 more
wiley   +1 more source

Application of colonoscopic auxiliary devices in reducing the polyp miss rate: a prospective randomized controlled study. [PDF]

BMC Gastroenterol
Li B, Liang Q, Chen Y, Luo W, Sun H, Xiong J, Chen Y, Xu S, Xiong G.   +8 more
europepmc   +1 more source

Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003–2020

Alimentary Pharmacology &Therapeutics, EarlyView.
Colectomy rates in ulcerative colitis have declined over the last two decades, coinciding with increased use of advanced therapies. These trends reflect significant changes in treatment approaches and provide valuable data to support informed decision‐making by patients, clinicians, and healthcare providers.
J. Couch, K. Thomas, T. R. Card, D. J. Humes   +3 more
wiley   +1 more source

Management of Post-Colonoscopy Syndrome with a Nutraceutical Intervention Based on <i>Hericium erinaceus</i>: A Retrospective Two-Arm Multicentre Analysis. [PDF]

Nutrients
Tursi A, D'Avino A, Brandimarte G, Mocci G, Pellegrino R, Federico A, Savarino EV, Gravina AG, The Hericium-Colon Study Group.   +8 more
europepmc   +1 more source

Evaluation of Mass Screening for Colorectal Cancer by Colonoscopy and Immunological Fecal Occult Blood Test

, 1995

openalex   +2 more sources

Improving Clinical Outcomes of Encapsulated Faecal Microbiota Transplantation for Clostridioides difficile Infection Through Empirical Donor Selection and Optimised Dosing: A Quality Improvement Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a large‐scale, multiple‐site Danish faecal microbiota transplantation (FMT) system, the cure rates in patients with Clostridioides difficile infection treated with encapsulated FMT were improved following exclusion of three low‐performing donors and implementation of a two‐dose FMT regimen.
Sara Ellegaard Paaske, Simon Mark Dahl Baunwall, Tone Rubak, Nina Rågård, Jens Kelsen, Mette Mejlby Hansen, Anders Bergh Lødrup, Søren Lyhne, Emilie Glavind, Christa Marie Culmback Fernis, Stine Hald, Lise Tornvig Erikstrup, Lars Vinter‐Jensen, Simon Lal, Susan Mikkelsen, Christian Erikstrup, Jens Frederik Dahlerup, Christian Lodberg Hvas   +17 more
wiley   +1 more source

Development of a convolutional neural network-based AI-assisted multi-task colonoscopy withdrawal quality control system (with video). [PDF]

Front Physiol
Chen J, Zhu M, Shen Z, Xia K, Xu X, Wang G.   +5 more
europepmc   +1 more source

High Risk of Colorectal Cancer After High‐Grade Dysplasia in Inflammatory Bowel Disease Patients

Alimentary Pharmacology &Therapeutics, EarlyView.
The advantages of colon‐sparing treatment for high‐grade dysplasia should be weighed against the higher risk of metachronous colorectal cancer and the subsequent need for stringent endoscopic surveillance. ABSTRACT Background There are limited data on colorectal cancer (CRC) risk after high‐grade dysplasia in inflammatory bowel disease.
Monica E. W. Derks, Maarten te Groen, Lauranne A. A. P. Derikx, Iris D. Nagtegaal, Frank Hoentjen   +4 more
wiley   +1 more source

Efficacy and safety of Shouhui Tongbian Capsules, a traditional Chinese medicine, combined with 2L polyethylene glycol for bowel preparation before colonoscopy: a multicenter, randomized, single-blind, parallel-controlled clinical trial. [PDF]

Therap Adv Gastroenterol
Ye F, Guo N, Wang Y, Wang B, Niu C, Ji Z, Guo M, Hou Y, Jian Y, Cui J, Chen D, Li S, Wang D, Guo H, Jiu J, Qiu C, Cao H, He Y, Chen M, Li H, Xin X, Zheng R, Chen W, Chen D, Niu L, Cui Z, Zou Z, Jia B, Zhang L, Bai Y, Li W, Yang X, Hua M, Long S, Cheng G, Huang Z, Yang E, Shi J, Zhang G.   +38 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source